No active regulatory warnings
1 Identity
Coenzyme Q10
Ubiquinone / Ubiquinol
Generally SafeEvidence: ModerateVitamin-LikeCoenzyme Q10 (CoQ10, ubiquinone-10) is a lipophilic benzoquinone that plays two essential roles: it is a critical electron carrier in the mitochondrial electron transport chain (Complex I → CoQ10 → Complex III) and a potent endogenous lipid-soluble antioxidant [1]. Every cell in the body synthesizes CoQ10 endogenously via the mevalonate pathway — the same pathway inhibited by statins (HMG-CoA reductase inhibitors), which reduce both cholesterol AND CoQ10 synthesis [2]. Tissue concentrations are highest in organs with high metabolic activity (heart, liver, kidney, skeletal muscle) and decline with aging [3]. Primary CoQ10 deficiency is a group of rare autosomal recessive mitochondrial disorders; secondary deficiency from statin therapy is far more common [4].
1
Coenzyme Q10
Ubiquinone / Ubiquinol
Generally SafeModerateVitamin-Like
Clinical verdict: CoQ10 is a critical mitochondrial electron carrier whose synthesis is reduced 20–40% by statins. Q-SYMBIO trial showed 43% MACE reduction in heart failure at 300 mg/day. No benefit proven for Parkinson disease (QE3 trial). Ubiquinol is 2–3× more bioavailable than ubiquinone. Take with fat-containing meals. Monitor INR if on warfarin [2] [5] [6].
RDA
Typical 100–300 mg
Target
>1.0 µg/mL (therapeutic); >2.0 µg/mL (some cardiology targets)
UL
Studied up to 1,200 mg
Category
Vitamin-Like
Population dosing
🔗 Best with: Vitamin E, Selenium, Alpha-Lipoic Acid✅ USP Verified, NSF Contents Certified, ConsumerLab Approved
2 Risk self-assessment
Statin therapy (inhibits mevalonate pathway, reducing CoQ10 synthesis by 20–40%) [2]
Aging (endogenous synthesis declines after age 30–40) [3]
Heart failure (increased utilization, reduced tissue levels) [5]
Primary CoQ10 deficiency (autosomal recessive mutations in COQ genes) [4]
Mitochondrial disorders [4]
Select factors above to see your risk level
4 Dietary sources
No established RDA exists for CoQ10 since it is synthesized endogenously [1]. Organ meats (heart, liver, kidney) are the richest dietary sources, followed by muscle meats and certain oils [7]. Dietary intake is estimated at 3–6 mg/day from a typical mixed diet — far below therapeutic supplemental doses of 100–300 mg/day [3]. Food sources cannot substitute for supplementation when therapeutic doses are needed.
5 Lab interpreter
Plasma CoQ10 (total ubiquinone + ubiquinol)
Your level:
Enter a value above
⚕ For healthcare professionals. Does not replace clinical judgment.
6 Quick facts
CategoryVitamin-Like
Safety levelGenerally Safe
EvidenceModerate
RDATypical 100–300 mg
Upper limit (UL)Studied up to 1,200 mg
Scientific nameUbiquinone / Ubiquinol
Chemical classLipophilic benzoquinone (2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone) [1]
Active formUbiquinol (reduced form, QH₂) [1]
Dual roleElectron transport chain carrier + lipid-soluble antioxidant [1]
Endogenous synthesisVia mevalonate pathway (same as cholesterol) [2]
Plasma reference0.5–1.5 µg/mL (varies widely with supplementation) [3]
Typical supplement dose100–300 mg/day [3]
Heart failure dose (clinical trials)300 mg/day (Q-SYMBIO trial) [5]
7 Dosage by population
Adults Moderate
See product label
Elderly Moderate
See product label
Consider reduced renal/hepatic clearance. Start at lower end of range.
Pregnancy Moderate
See guidance
No established RDA. Small trials suggest possible preeclampsia prevention benefit. Generally considered safe at 100–200 mg/day, but data are limited. Consult obstetric provider [3].
Pediatric Moderate
See guidance
Primary CoQ10 deficiency presenting in childhood (nephrotic syndrome, cerebellar ataxia, encephalomyopathy) is treated with 5–30 mg/kg/day — early treatment can prevent irreversible organ damage [4]. No routine supplementation indicated in healthy children.
Athletes Limited
Standard dose
Obesity Limited
Standard dose
Fat-soluble compounds may require dose adjustment in obesity.
Renal Limited
Consult specialist
Dose adjustment may be needed in renal impairment.
Vegan Moderate
Standard dose
CoQ10 is fat-soluble — take with a fat-containing meal for optimal absorption. Ubiquinone absorption is approximately 3%; ubiquinol approximately 6–9% [3]. Therapeutic doses in clinical trials: 100–300 mg/day for statin myopathy; 300 mg/day for heart failure (Q-SYMBIO); up to 1,200 mg/day for Parkinson disease (no benefit shown at this dose in QE3 trial) [4] [5] [6].
8 Form comparison
| Form | Bioavailability | Vegan | Cost/day |
|---|---|---|---|
| ['Ubiquinone (oxidized CoQ10)', 'common', 'Standard supplemental form. Must be reduced to ubiquinol in the body to function as an antioxidant. Well-studied. Lower cost [1].'] | Standard | Check label | |
| ['Ubiquinol (reduced CoQ10)', 'preferred', 'The bioactive, reduced form. Approximately 2–3× greater bioavailability than ubiquinone. May be preferred in elderly or individuals with impaired reduction capacity (heart failure, liver disease) [3].'] | Standard | Check label | |
| ['Solubilized/nano-formulations', '', 'Various formulations using cyclodextrin, liposomes, or oil-based soft gels to enhance absorption. Bioavailability varies by product [3].'] | Standard | Check label |
9 Clinical evidence
Strong evidence
Essential role in mitochondrial electron transport chain — genetic primary CoQ10 deficiency causes encephalomyopathy, nephrotic syndrome, and cerebellar ataxia, treated with high-dose CoQ10 supplementation [4]. Statins inhibit CoQ10 synthesis via mevalonate pathway suppression — this is well-established biochemically [2]. HIGH
Moderate evidence
Heart failure: the Q-SYMBIO trial (n = 420, randomized, double-blind) showed that CoQ10 300 mg/day reduced major adverse cardiovascular events by 43% and all-cause mortality by 42% over 2 years [5]. Statin-associated myopathy: meta-analysis of 12 RCTs showed modest reduction in statin-related muscle symptoms with CoQ10 supplementation, though results are inconsistent [8]. Migraine prevention: a small RCT (n = 42) showed CoQ10 300 mg/day reduced migraine frequency by 48% vs 14% placebo [3]. Preeclampsia prevention: a small trial showed reduced risk with CoQ10 supplementation from 20 weeks gestation [3]. MODERATE
Insufficient evidence
Parkinson disease: the QE3 Phase III trial (n = 600) found no benefit of CoQ10 at 1,200 or 2,400 mg/day vs placebo for early PD [6]. Athletic performance in healthy individuals: no convincing benefit [3]. Male fertility: some positive small studies but insufficient for recommendation [3]. Huntington disease: no benefit in Phase III trial [3]. LOW
10 Safety
🚩 Red flags — when to stop and refer
● Warfarin patient starting CoQ10 — check INR within 1–2 weeks (structural similarity to vitamin K) [3]
● Child with steroid-resistant nephrotic syndrome — consider primary CoQ10 deficiency (genetic testing) [4]
● Patient attributing statin intolerance solely to CoQ10 depletion and refusing statins — important to distinguish myalgia from true myopathy; statins save lives [2]
Pregnancy
No established RDA. Small trials suggest possible benefit for preeclampsia prevention. CoQ10 is generally considered safe in pregnancy at standard doses (100–200 mg/day), but data are limited [3]. Consult obstetric provider before supplementing in pregnancy.
Pediatric
Primary CoQ10 deficiency presenting in childhood (nephrotic syndrome, cerebellar ataxia, encephalomyopathy) is treated with 5–30 mg/kg/day — early treatment can prevent irreversible organ damage [4]. No routine supplementation indicated in healthy children.
11 Toxicity and overdose
12 Drug interactions
Warfarin Major
Mechanism: CoQ10 (ubiquinone) is structurally similar to vitamin K₂. May promote coagulation and reduce warfarin efficacy. [3]
Effect: Reduced INR. Potential thromboembolic events if warfarin dose is not adjusted. [3]
Action: Check INR within 1–2 weeks of starting CoQ10. Monitor closely with dose changes [3].
Statins (atorvastatin, rosuvastatin, etc.) Moderate
Mechanism: Statins inhibit HMG-CoA reductase (mevalonate pathway), reducing endogenous CoQ10 synthesis by 20–40%. [2]
Effect: Reduced plasma CoQ10. Possible contribution to statin myopathy. [2]
Action: CoQ10 100–200 mg/day is reasonable if statin-associated muscle symptoms occur [8].
Antihypertensives Minor
Mechanism: CoQ10 may have modest blood pressure lowering effects (meta-analyses suggest ~3–5 mmHg systolic reduction). [3]
Effect: Additive blood pressure reduction; risk of hypotension in patients on multiple antihypertensives. [3]
Action: Monitor blood pressure, especially during dose adjustments [3].
Chemotherapy agents (doxorubicin) Moderate
Mechanism: Doxorubicin causes cardiotoxicity partly via mitochondrial damage and ROS. CoQ10 is cardioprotective in animal models. [1]
Effect: Potential cardioprotection. Theoretical concern about reducing chemotherapy efficacy (antioxidant interference), though clinical data are limited. [1]
Action: Discuss with oncologist before supplementing during chemotherapy [1].
13 Supplement interactions
Best combined with
Vitamin E · 15 mg/day vitamin E (RDA)
CoQ10 regenerates oxidized vitamin E (alpha-tocopherol) back to its active form, and both protect cell membranes from lipid peroxidation [1].
CoQ10 regenerates oxidized vitamin E (alpha-tocopherol) back to its active form, and both protect cell membranes from lipid peroxidation [1].
Selenium · 100–200 µg/day selenium
The KiSel-10 trial showed that combined selenium + CoQ10 supplementation (200 µg Se + 200 mg CoQ10) reduced cardiovascular mortality by 49% in elderly Swedish adults over 5 years [3].
The KiSel-10 trial showed that combined selenium + CoQ10 supplementation (200 µg Se + 200 mg CoQ10) reduced cardiovascular mortality by 49% in elderly Swedish adults over 5 years [3].
Alpha-Lipoic Acid · 300–600 mg/day ALA
Both are mitochondrial antioxidants. ALA regenerates CoQ10 in the mitochondrial membrane [1].
Both are mitochondrial antioxidants. ALA regenerates CoQ10 in the mitochondrial membrane [1].
14 Laboratory monitoring
Plasma CoQ10 (total ubiquinone + ubiquinol) Primary
Target: >1.0 µg/mL (therapeutic); >2.0 µg/mL (some cardiology targets) · If monitoring supplementation response in heart failure or primary deficiency [3].
Plasma CoQ10 reflects supplementation status, not tissue status. Levels rise with supplementation and return to baseline within 2 weeks of stopping [3].
INR (if on warfarin) Secondary
Target: Per anticoagulation target · Within 1–2 weeks of starting CoQ10; with dose changes [3].
Muscle CoQ10 biopsy Secondary
Target: Lab-specific reference · If primary CoQ10 deficiency suspected [4].
CK (creatine kinase) Secondary
Target: <5× ULN · If evaluating statin myopathy [8].
15 Deficiency and prevalence
Risk factors
• Statin therapy (inhibits mevalonate pathway, reducing CoQ10 synthesis by 20–40%) [2]
• Aging (endogenous synthesis declines after age 30–40) [3]
• Heart failure (increased utilization, reduced tissue levels) [5]
• Primary CoQ10 deficiency (autosomal recessive mutations in COQ genes) [4]
• Mitochondrial disorders [4]
16 Frequently asked questions
Should I take CoQ10 if I'm on a statin? ▼
This is the most common question and remains debated. Statins do reduce CoQ10 synthesis by 20–40% [2]. Some meta-analyses suggest CoQ10 modestly reduces statin-related muscle symptoms, but results are inconsistent [8]. There is no universal guideline recommending routine CoQ10 with statins. It is reasonable to try 100–200 mg/day if experiencing statin-related muscle symptoms.
Is ubiquinol better than ubiquinone? ▼
Ubiquinol (the reduced form) has approximately 2–3× greater bioavailability than ubiquinone [3]. It may be preferred in elderly patients, heart failure, or those not responding to ubiquinone. However, both forms are converted back and forth in the body, and ubiquinone is well-studied and effective in clinical trials (including Q-SYMBIO, which used ubiquinone).
Does CoQ10 help heart failure? ▼
The Q-SYMBIO trial (n = 420) showed 43% reduction in MACE and 42% reduction in mortality with 300 mg/day over 2 years [5]. This is the strongest clinical trial evidence. However, it was a single trial and not yet replicated at scale. Current ESC/AHA heart failure guidelines do not formally recommend CoQ10, but some cardiologists use it as adjunctive therapy.
Can CoQ10 treat Parkinson disease? ▼
Despite early promise, the definitive QE3 Phase III trial (n = 600) showed no benefit of CoQ10 at any dose (1,200 or 2,400 mg/day) versus placebo for early Parkinson disease [6]. It is not recommended for this indication.
17 Regulatory status
United States (FDA): Classified as a dietary supplement. No RDA established (endogenously synthesized). No FDA-approved health claims. Marketed for heart health and energy [1].
European Union (EFSA): No authorized health claims. Classified as a food supplement. Widely available OTC across Europe [3].
Japan (MHLW): CoQ10 was a prescription drug in Japan until 2001 (for heart failure). Now available as a food supplement. One of the most popular supplements in Japan [3].
South Korea (MFDS): Available as dietary supplement. Approved claims: antioxidant activity.
18 References
[1]Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271(1):195-204. doi:10.1016/0925-4439(95)00028-3 REVIEW
[2]Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007;7 Suppl:S168-S174. doi:10.1016/j.mito.2007.03.002 REVIEW
[3]National Institutes of Health, Office of Dietary Supplements. Coenzyme Q10 — Fact sheet for health professionals. Updated 2024. ods.od.nih.gov REVIEW
[4]Emmanuele V, et al. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol. 2012;69(8):978-983. doi:10.1001/archneurol.2012.206 REVIEW
[5]Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-649. doi:10.1016/j.jchf.2014.06.008 RCT
[6]Beal MF, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-552. doi:10.1001/jamaneurol.2014.131 RCT
[7]U.S. Department of Agriculture. FoodData Central. fdc.nal.usda.gov GOVERNMENT
[8]Banach M, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24-34. doi:10.1016/j.mayocp.2014.08.021
19 US supplement products
25
on-market US dietary supplements contain Coenzyme Q10
Source: NIH Dietary Supplement Label Database (DSLD). Cross-referenced with SupplementIndex safety profiles.
Top brands
Solgar5 products
Life Extension3 products
Nature Made3 products
The Vitamin Shoppe3 products
NFH2 products
Blueprint Bryan Johnson1 products
CTD Sports1 products
CurEase1 products
Integrative Therapeutics1 products
Jigsaw Health1 products
Product forms
Softgel Capsule (15)Capsule (5)Tablet or Pill (2)Liquid (1)Other (e.g. tea bag) (1)Powder (1)Sample products
Essential Capsules Blueprint Bryan JohnsonCapsule
Multi Elite CTD SportsTablet or Pill
Pure CoQ10 Powder CurEasePowder
Vitaline CoQ10 Integrative TherapeuticsTablet or Pill
A.M. Jigsaw HealthOther (e.g. tea bag)
20 Frequently paired with
Ingredients most often found in the same supplement products as Coenzyme Q10, based on NIH DSLD data.
21 Related articles
📰 Article placeholder — auto-populated via news.gmj.ge
📰 Article placeholder — auto-populated via news.gmj.ge
📰 Article placeholder — auto-populated via news.gmj.ge
📰 Article placeholder — auto-populated via news.gmj.ge
Auto-updated from GMJ Newsroom. Articles tagged "Coenzyme Q10" appear here.
22 Cite this page
Vancouver
Pkhakadze G. Coenzyme Q10 — safety profile [Internet]. Tbilisi: Public Health Institute of Georgia; 2026 [cited 2026 May 30]. Available from: https://supplement.ge/ingredients/coenzyme-q10/
APA 7th
Pkhakadze, G. (2026). Coenzyme Q10 — Safety profile. Public Health Institute of Georgia. https://supplement.ge/ingredients/coenzyme-q10/
CC BY 4.0
🛡 SupplementIndex receives no funding from supplement manufacturers. All content independently authored by PHIG.
GP
Reviewed by Prof. G. Pkhakadze, MD, MPH, PhD
Editor-in-Chief, Georgian Medical Journal · Chair, PHIG
Last reviewed: May 2026 · Next: November 2026
This entry is provided for educational and public health purposes under CC BY 4.0. Consult your healthcare provider before starting any supplement. For corrections: info@accreditation.ge.
Publisher: PHIG · Editor-in-Chief: Prof. Giorgi Pkhakadze, MD, MPH, PhD
Publisher: PHIG · Editor-in-Chief: Prof. Giorgi Pkhakadze, MD, MPH, PhD